Article

High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone Lymphoma

2025-10-26

Abstract excerpt

B-cell receptor (BCR) signaling is a key therapeutic target in B-cell lymphomas, and Bruton tyrosine kinase inhibitors (BTKi) have demonstrated clinical efficacy in marginal zone lymphoma (MZL). However, the rate of complete remissions is relatively low, and resistance remains a significant clinical challenge, underscoring the need for novel combination strategies. To identify compounds that enhance the activity o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 64c65831-0ad0-5daf-9cad-a14aaff1ba4b
DOI: 10.1101/2025.10.25.684506

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone LymphomaDOI 10.1101/2025.10.25.684506Read

Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclaxSemantic proximity Read

Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.Semantic proximity Read

CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitorsSemantic proximity Read

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.Semantic proximity Read

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsSemantic proximity Read

Optimizing therapy for nodal marginal zone lymphomaSemantic proximity Read

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsSemantic proximity Read

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and PerspectivesSemantic proximity Read

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasSemantic proximity Read

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.Semantic proximity Read

Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.Semantic proximity Read